ContraFect to Present at 10th Annual Biotech Showcase
January 03 2018 - 7:00AM
ContraFect Corporation (NASDAQ:CFRX), a
biotechnology company focused on the discovery and development of
protein and antibody therapeutics for life-threatening,
drug-resistant infectious diseases, today announced that Steven C.
Gilman, Ph.D., the Company's Chairman and Chief Executive Officer,
will present a corporate overview at the 10th Annual Biotech
Showcase on Tuesday, January 9, 2018 at 10:00 AM PT (1:00 PM ET) in
San Francisco, CA. The focus of the presentation will be on
ContraFect's lead program, CF-301, currently in a Phase 2 clinical
trial, and the Company's novel approach to the treatment of
drug-resistant Staphylococcus aureus (Staph aureus) infections,
including Methicillin-resistant Staph aureus (MRSA).
The presentation will be available as a webcast for a limited
time. To access via the Company's website, please go to
www.contrafect.com. To access the webcast directly, please use the
following URL:
https://event.webcasts.com/starthere.jsp?ei=1175922&tp_key=6d0289cf40
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA and influenza.
ContraFect is also conducting research focused on the discovery of
lysins to target Gram-negative bacteria.
About CF-301:
CF-301 is a recombinant bacteriophage-derived lysin with potent
bactericidal activity against Staphylococcus aureus (Staph aureus),
a major cause of blood stream infections, or bacteremia. CF-301 has
the potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus and therefore should not
impact the body's natural bacterial flora. By targeting a conserved
region of the cell wall that is vital to bacteria, resistance is
unlikely to develop to CF-301. Combinations of CF-301 with standard
of care (SOC) antibiotics significantly increased bacterial killing
and survival in animal models of disease when compared to treatment
with antibiotics or CF-301 alone. In addition, in vitro and in vivo
experiments have shown that CF-301 is highly active against biofilm
infections. CF-301 was licensed from The Rockefeller University and
is being developed at ContraFect and is the first lysin to enter
clinical studies in the U.S.
Forward-Looking Statements
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, our ability
to address life threatening infections using our therapeutic
product candidates from our lysin and monoclonal antibody platforms
to target conserved regions of either bacteria or viruses, whether
our initial product candidates can treat antibiotic-resistant
infections such as MRSA (Methicillin-resistant Staph aureus) and
influenza, our ability to discover new lysins targeting
Gram-negative bacteria, and the potential for CF-301 to be a
first-in-class treatment for Staph aureus bacteremia.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contact
Paul Boni
ContraFect Corporation
Tel: 914-207-2300
Email: pboni@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024